Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

56.48
+0.43000.77%
Pre-market: 88.7232.24+57.08%08:50 EDT
Volume:2.40M
Turnover:135.10M
Market Cap:8.40B
PE:-7.38
High:57.00
Open:56.76
Low:55.84
Close:56.05
52wk High:65.00
52wk Low:39.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:1.72
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.05
PE(LYR):-10.03

Loading ...

Vaxcyte Shares Surge as Pneumococcal Vaccine Meets Main Trial Goals

Reuters
·
2 hours ago

S&P 500 Futures Decline in Premarket Trading; Vaxcyte, PTC Lead

Dow Jones
·
1 hour ago

Vaxcyte price target raised to $125 from $116 at Guggenheim

TIPRANKS
·
1 hour ago

Top Premarket Gainers

MT Newswires Live
·
1 hour ago

Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial

Dow Jones
·
2 hours ago

U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte

Reuters
·
2 hours ago

Vaxcyte Surges on Pneumococcal Vaccine Late-Stage Trial Success

Reuters
·
2 hours ago

Vaxcyte announces ‘positive’ results from OPUS-1 Phase 3 trial of VAX-31

TIPRANKS
·
2 hours ago

Vaxcyte Shares Jump 25.6% Premarket After Co's Pneumococcal Vaccine Meets Late-Stage Trial Goals

THOMSON REUTERS
·
2 hours ago

Vaxcyte - Vax-31 Meets All Prespecified Primary Endpoints Across Age Groups Compared to Pcv20 And/or Pcv21

THOMSON REUTERS
·
2 hours ago

Vaxcyte, Inc.: to Report Results from Opus-2 and Opus-3 Adult Phase 3 Trials in First Half of 2027

THOMSON REUTERS
·
2 hours ago

Vaxcyte - Vax-31 Meets Noninferiority for All 32 Serotype Comparisons in Adults 18-49 vs 50-64

THOMSON REUTERS
·
2 hours ago

Vaxcyte Reports Positive Topline Data from Opus-1, the Pivotal Adult Phase 3 Trial of Vax-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

THOMSON REUTERS
·
2 hours ago

Vaxcyte Sets Oct. 5 Webcast to Release Phase 3 OPUS-1 Topline Data for VAX-31 Pneumococcal Vaccine Candidate

Reuters
·
15 hours ago

Vaxcyte EVP, Chief Scientific Officer and COO Jim Wassil Disposes of USD 127,561 in Common Shares

Reuters
·
Oct 03

Mizuho biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Oct 02

Vaxcyte Price Target Cut to $130.00/Share from $133.00 by B of a Securities

Dow Jones
·
Sep 29

Vaxcyte VAX-31 Positioned to Validate Broad Coverage, BofA Says

MT Newswires Live
·
Sep 28

Vaxcyte, Inc. : Bofa Global Research Cuts Price Objective to $130 from $133

THOMSON REUTERS
·
Sep 28

BofA Securities Adjusts Vaxcyte Price Target to $130 From $133, Maintains Buy Rating

MT Newswires Live
·
Sep 28